Our partner Asahi Kasei Pharma expects to obtain study in the second half ofesccort will be the next major milestone for potentially making Cresemba available for patients in Japan. The study enrolled patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. DisclaimerThis communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Wes Ltd.
In-market sales reported as moving annual total MAT in U.
About BasileaBasilea Pharmaceutica Ltd. The registration status and approved indications may vary from country to country.
Basilea received an upfront payment of CHF 7 million and will be eligible to receive up to approximately CHF 60 million of additional payments upon achievement of regulatory and commercial milestones. Basilea Pharmaceutica Ltd. Both infections are associated with high morbidity and mortality.
The total of people discharged reached 1,00,16, while death toll stood at 1,50, after people succumbed to the virus in the last 24 hours. While practical classes for final year students will begin from February, theory classes would be held online.
Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actualfinancial condition, performance or achievements of Basilea Pharmaceutica Ltd. Basilea will also receive double-digit tiered royalties on product sales in Japan.
Dollar corrected for currency fluctuations. Additional information can be found at Basilea's website www.
Cresemba has been approved in more than 50 countries to date and is currently marketed in 48 countries, including the United States, most EU member states and several additional countries inside and outside of Europe. Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive to develop and commercialize isavuconazole in Japan. About invasive aspergillosis and mucormycosisInvasive aspergillosis and mucormycosis are life-threatening fungal infections that predominantly affect immunocompromised patients, such as patients escorh hematologic malignancies blood cancer.